Haisco
Haisco Pharmaceutical Group is a Chinese healthcare company focused on the research and development of therapeutic drugs.
Launch date
Employees
Market cap
CAD6.9b
Enterprise valuation
CAD7.0b (Public information from Sep 2024)
Share price
CNY33.02 002653.SZ
Tibet China (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 3.3b | 2.8b | 3.0b | 3.4b | 4.0b | 5.0b | 6.2b |
| % growth | (15 %) | (17 %) | 9 % | 11 % | 19 % | 25 % | 24 % |
| EBITDA | 841m | 694m | 607m | 576m | 602m | 927m | 1.3b |
| % EBITDA margin | 25 % | 25 % | 20 % | 17 % | 15 % | 19 % | 21 % |
| Profit | 637m | 345m | 277m | 295m | 402m | 594m | 948m |
| % profit margin | 19 % | 12 % | 9 % | 9 % | 10 % | 12 % | 15 % |
| EV / revenue | 5.6x | 7.8x | 7.9x | 7.6x | 8.6x | 6.9x | 5.5x |
| EV / EBITDA | 22.1x | 31.3x | 39.1x | 44.4x | 57.2x | 37.1x | 27.0x |
| R&D budget | 406m | 434m | 448m | 517m | - | - | - |
| R&D % of revenue | 12 % | 16 % | 15 % | 15 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Related Content
Recent News about Haisco
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
ACQUISITION by Asensus Surgical Sep 2018
